Companies
Vaxcyte closes about $1.15 billion in equity and convertible offerings
Vaxcyte closed concurrent equity and 1.5% convertible notes for about $1.15B gross; underwriter options exercised; proceeds aim at VAX-31 adult and infant programs.
Newsroom desk
TickerGrove Healthcare Desk
Healthcare and biotechnology issuers from primary filings and official releases.
Desk contributor: Claire Morgan
Reporting from TickerGrove Healthcare Desk, grounded in primary documents, with figures and developments clearly dated.
How TickerGrove checks a claim
Recent articles
Companies
Matchpoint closes $150 million Series B for oral autoimmune pipeline
Nextech and Norwest co-led; proceeds fund MPT-062 clinical proof of concept from 2027 and a continuing Novartis-funded program; Fierce Biotech also cites a $70 million Series A and $60 million Novartis upfront.
Companies
FDA clears Novartis Rhapsido as first treatment for symptomatic dermographism
RemIND showed a Week 12 complete Total Fric Score response of 29.3% with remibrutinib versus 14.0% with placebo; the label dose is 25 mg twice daily and carries a bleeding warning.
Companies
FDA clears Pfizer Tukysa with trastuzumab and pertuzumab for HER2 maintenance
HER2CLIMB-05 showed median progression-free survival of 24.9 months with tucatinib versus 16.3 months with placebo after induction, for a hazard ratio of 0.64; the label carries a boxed hepatotoxicity warning.
Companies
Asahi Kasei wins U.S. approval for oral Hovilpri in refractory herpes lesions
The Food and Drug Administration cleared the helicase-primase inhibitor for immunocompromised adults whose mucocutaneous sores did not respond to standard antivirals, with 63% healed by day 28 versus 34% on investigator's choice.
Companies
FDA clears Tecentriq with chemo after surgery for Stage III dMMR colon cancer
Atomic trial: disease-free survival hazard ratio 0.50; 36-month disease-free survival 86% with Tecentriq plus chemo versus 76% with chemo alone; twelfth U.S. Tecentriq indication.
Companies
Teva wins U.S. approval for monthly schizophrenia shot Weltruza
The once-monthly under-the-skin olanzapine shot is cleared for adults with schizophrenia; Teva says it needs no loading doses, oral top-up, or post-injection monitoring and will launch in coming weeks.
Companies
Humana beats its 2027 Medicare Star Ratings target and keeps its $9 profit guide
CMS final 2027 Stars (Bonus Year 2028) put Humana above its peer-median Stars revenue target; the insurer also affirmed at least $9.00 in 2026 adjusted earnings per share as open enrollment nears.